Home › Companies › KAPA

Kairos Pharma

KAPA Lead: Phase 2 ★ Read the deep dive → 1 Biotech Distilled article ↓

Oncology Cell Peptide Protein Small Molecule

Most recent annual filing: 2026-03-31

Catalyst timeline

5 trackedQuarter catalyst calendar →

ENV-105 lung Ph1 interim2026ENV-105 lung Ph1 interim, 2026, material
ENV-105 prostate Ph2 topline3Q 2026ENV-105 prostate Ph2 topline, 3Q 2026, thesis-defining
KROS-741 cMET inhibitor IND filing3Q 2026KROS-741 cMET inhibitor IND filing, 3Q 2026, notable
KROS-101 GITRL partnership3Q 2026KROS-101 GITRL partnership, 3Q 2026, routine
NCT05534646 readoutJan 2027NCT05534646 readout, Jan 2027, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (9 active programs)

carotuximab

ENV 105

Protein Target: CD105, endoglin

Prostate Cancer Phase 2 Cedars-Sinai Medical Center NCT05534646
Non-Small Cell Lung Cancer Phase 1 Cedars-Sinai Medical Center NCT05401110

ENV 105

Protein Target: CD105, endoglin

Head and Neck Cancer Preclinical

ENV 205

Protein Target: mitochondrial DNA

Prostate Cancer Preclinical

KROS 101

Small Molecule Target: GITR ligand, GITRL

Undisclosed indication Preclinical oral

KROS 102

Small Molecule Target: GITR

Undisclosed indication Preclinical

KROS 201

Cell Target: cancer stem cells

Glioblastoma Preclinical intravenous

KROS 301

Small Molecule Target: RelA, NF-KB

Undisclosed indication Preclinical

KROS 401

Peptide Target: IL-4, IL-13, IL13R alpha1, IL4R alpha1

Triple Negative Breast Cancer Preclinical

Biotech Distilled coverage (1)

2026-08-18 Kairos Pharma (KAPA) - Scientific Deep Dive for ENV-105 and Pipeline Products

Articles open on Substack. Some deep dives are subscriber-only.